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Little information is available describing viral loads in body fluids other than blood. In addition, the
suitability of commercially available assays for human immunodeficiency virus type 1 (HIV-1) RNA quanti-
tation has not been evaluated in most nonblood fluids. We compared Organon Teknika’s nucleic acid sequence-
based amplification method (NASBA) and Roche’s Amplicor HIV-1 Monitor (reverse transcriptase PCR
[RT-PCR]) for quantitating HIV-1 RNA in cerebrospinal fluid (CSF), saliva, breast milk, seminal plasma, and
cervical-vaginal lavage fluid (CVL). Saliva and breast milk frequently demonstrated some inhibition in the
RT-PCR assay, similar to the inhibition previously described in seminal plasma. Inhibition of the RT-PCR
assay was not observed with CSF or CVL, nor in any of the NASBA assays. When fluids from HIV-infected
individuals were tested by RT-PCR and NASBA, 73 and 27% of CSF samples and 60 and 40% of breast milk
specimens had detectable RNA, respectively. These differences were not statistically significant. In cross-
sectional studies using RT-PCR to measure viral RNA in paired blood plasma and CSF samples, 71% of blood
plasma samples and 42% of CSF samples were positive. A similar analysis using NASBA with paired blood
plasma and CVL, saliva, or seminal plasma samples revealed 91% were blood plasma positive and 55% were
CVL positive, 76% were blood plasma positive and 46% were saliva positive, and 83% were blood plasma
positive and 63% were seminal plasma positive. NASBA worked fairly well to quantitate HIV-1 RNA from all
fluids without apparent inhibition. RT-PCR performed well on CVL and CSF, frequently with greater sensi-
tivity, although its use in other fluids appears limited due to the presence of inhibitors. These studies
demonstrate that viral loads in nonblood fluids were generally lower than in blood.
Although human immunodeficiency virus (HIV) in the pe-
ripheral blood compartment has been the focus of consider-
able research over the past 15 years, much less work has been
directed at HIV in nonblood compartments. Other compart-
ments, such as the genital tract, nervous system, breast, and
oral cavity, may be potential sanctuary sites harboring HIV and
impacting both the transmission and pathogenesis of HIV in-
fection. It is vital to investigate tissues and compartments other
than blood for two important reasons. From a patient perspec-
tive, it is important to determine whether antiretroviral therapy
can reduce viral load in nonblood compartments which can
serve as potential reservoirs of viral replication, particularly in
individuals whose systemic viral load has been substantially
reduced via potent drug therapy (29, 30). From a public health
perspective, it is critical to know the factors that contribute to
the “infectiousness” of an individual in order to devise strate-
gies to reduce the likelihood of transmission (21). Increased
viral load in seminal plasma, cervical fluid, breast milk, and,
potentially, saliva, likely contributes to increased transmission
risks.
Previous studies quantifying HIV in other compartments
have involved noncommercial assays, making comparisons be-
tween different studies problematic (10, 13, 15, 16, 23). Since
it is often difficult to obtain specimens other than blood
from patients, many of these studies have involved relative-
ly few numbers of patients. There are three commonly used
commercially available HIV RNA assays: Roche’s Ampli-
cor HIV-1 Monitor (reverse transcriptase PCR [RT-PCR]),
Organon-Teknika’s nucleic acid sequence-based amplification
(NASBA), and Chiron’s signal amplification assay (Quanti-
plex). The Roche Amplicor HIV-1 Monitor is an in vitro nu-
cleic acid amplification test for the quantitation of HIV-1 RNA
by using RT-PCR technology. NASBA, and its recently im-
proved version, NucliSens HIV-1 QT, are isothermal NASBA
assays for the quantitative determination of HIV-1 RNA. The
NASBA-based assay incorporates a silica bead nucleic acid
extraction process (1), and amplification is based on repeated
transcription via T7 RNA polymerase. The Quantiplex assay
relies on signal amplification through branched DNA, rather
than target amplification. Both NASBA and RT-PCR require
at least 0.2 ml of sample for most applications, whereas the
Quantiplex requires at least 1 ml. Limited sample volumes of
some body fluids may preclude the utility of the Quantiplex
assay. Accordingly, in this study, we have evaluated only RT-
PCR and NASBA for quantitating HIV-1 RNA in cerebrospi-
nal fluid (CSF), seminal plasma, cervical vaginal lavage fluid
(CVL), breast milk, and saliva.
We previously observed considerable inhibition of the RT-
PCR when seminal plasma was assayed, but no inhibition with
the NASBA assay (4). Therefore, as we began to study other
body fluids, we initially tested a small number of samples from
HIV-infected patients as well as specimens from uninfected
individuals spiked with HIV to detect the presence of ampli-
fication inhibitors. After determining the better assay for each
body fluid, a cross-sectional study was performed to quantitate
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HIV RNA in paired blood plasma and CSF samples, seminal
plasma, CVL, or saliva samples.
(This study was presented in part at the 6th Conference on
Retroviruses and Opportunistic Infections, Chicago, Ill., 31
January–4 February 1999 [abstr. 295].)
MATERIALS AND METHODS
Patients and samples. HIV-1-infected patients participating in a variety of
studies had blood and another body fluid obtained following informed consent.
Breast milk and saliva samples were also obtained from consenting uninfected
donors. The Institutional Review Board of the University of North Carolina at
Chapel Hill approved all studies.
Whole blood for plasma was collected in either EDTA or acid-citrate-dex-
trose-anticoagulated tubes. CSF was collected in 10-ml sterile polypropylene
tubes as described by Robertson et al. (19). Five milliliters of whole unstimulated
saliva was collected in a sterile 50-ml centrifuge tube kept chilled on ice. Subjects
abstained from eating or brushing their teeth for at least 30 min prior to saliva
collection (25). Breast milk was expressed manually or with a breast pump into
sterile containers (13). Semen was collected by masturbation without the use of
lubricants or water (4). CVL samples were collected by bathing the cervical os
with 10 ml of normal saline and collecting the fluid that pooled in the posterior
fornix in a sterile 15-ml test tube (26).
All specimens were processed within 2 to 6 h of collection. Saliva and CVL
samples were vortexed and then stored as 0.5- to 1.0-ml aliquots at 270°C until
tested. All other specimens (blood, semen, breast milk, and CSF) were centri-
fuged at room temperature at 400 to 600 3 g for 10 min. The lipid layer of the
breast milk specimens was removed by using a wide-bore pipette and discarded.
Cell-free supernatants for all specimens except saliva and CVL were carefully
removed and stored in 0.5- to 1.0-ml aliquots at 270°C until tested. Because
CVL is initially collected in approximately 10 ml of diluent and the CVL-specific
volume is unknown, no dilution factor was calculated into the final results. In
some instances, cultured primary HIV isolates from recently infected infants (;
5 3 106 HIV-1 RNA copies/ml) were added to cell culture medium or body fluids
(saliva and breast milk) from uninfected individuals in virus spiking experiments
to investigate the presence of amplification inhibitors.
HIV RNA assays. The Roche Amplicor HIV-1 Monitor (Branchburg, N.J.)
and Organon Teknika (Durham, N.C.) NASBA assays were performed by fol-
lowing the manufacturer’s instructions. During the course of this investigation,
Organon Teknika modified the NASBA assay to improve the sensitivity. There-
fore, some of the data reported here were obtained with the older NASBA
version, while other results were obtained with the more recent version, Nu-
cliSens HIV-1 QT. The two assays, however, have been reported to yield com-
parable results (T. D. Ly, B. Montes, J. E. Molkin, and M. Segondy, Abstr. 5th
Conf. Retroviruses Opportunistic Infect., abstr. 309, 1998).
The Roche Monitor utilizes an internal quantitation standard (QS) which is
incorporated into each individual sample at a known copy number. HIV-1 RNA
levels in test specimens are determined by comparing the test HIV-1 signal to the
QS signal for each sample. Maximum recovery of QS is observed when the
second QS well has an optical density (OD) of 0.3 or greater. We defined partial
inhibition as use of the first QS well with an OD of ,1.0. Complete inhibition of
amplification was defined as both QS wells with an OD of ,0.3. The dynamic
range for this assay is 400 to 750,000 HIV RNA copies/ml.
Quantitation in the NASBA or NucliSens assay is achieved by coamplification
of the HIV-1 sample RNA together with internal calibrators (Qa, Qb, and Qc).
No inhibition is observed when there is total recovery of the Qa, Qb, and Qc
internal calibrators. Partial inhibition is exhibited with low recovery of Qa, Qb,
or Qc as defined by the Organon Teknika software. No recovery of Qa, Qb, or
Qc signifies complete inhibition of amplification. The upper limit of detection for
both assays is 1.0 3 107 log HIV RNA copies/ml. The lower limit for the older
NASBA assay is 1,000 HIV RNA copies/ml when the calibrators are diluted 1:10.
The more sensitive NucliSens assay has a lower limit of 400 HIV RNA copies/ml.
The NASBA and NucliSens assays can achieve greater sensitivity when the
sample volume is increased. In this study, we took advantage of this property
when testing the CVL and saliva samples, typically using 1 ml of specimen when
available.
Statistical analysis. Blood plasma and body fluid HIV RNA levels were log10
transformed prior to analysis. Fisher’s exact test was used to compare the sen-
sitivities of the two assays. Correlations of blood plasma with seminal plasma,
CVL, and CSF viral loads were made by regression analysis with SigmaStat 2.0
software (SSPS, Inc., Chicago, Ill.).
RESULTS
Comparative performance of RT-PCR and NASBA-based
HIV-1 RNA assays with different biological fluids. CVL and
CSF samples from infected individuals and breast milk and
saliva from uninfected individuals spiked with HIV were tested
for the presence of inhibitors in both HIV RNA assays (Table
1). Results from our previous analysis of seminal plasma (4)
are provided for comparison. Partial inhibition was frequently
observed when saliva (67% inhibited) and breast milk (38%
inhibited) were assayed by RT-PCR, as evidenced by low re-
covery of the internal quantitation standard (QS) used for
calculating viral load (Table 1). In comparison, 96% of the
seminal plasma samples we tested earlier showed at least some
inhibition and 20% demonstrated complete inhibition in the
RT-PCR assay, as determined by low OD in the QS wells. CVL
and CSF did not appear to contain inhibitors when tested in
the RT-PCR assay. No inhibition was observed for any of the
body fluids tested in the NASBA and NucliSens assays, con-
firming our previous results with seminal plasma (4).
Although the RT-PCR assay frequently showed inhibition in
some of the body fluids, it often displayed greater sensitivity
than the NASBA or NucleiSens assay (Table 2). This was
particularly evident in breast milk and CSF specimens, where
the viral load was usually low (typically ,104 copies/ml). The
TABLE 1. CVL and CSF from HIV-infected patients and breast
milk and saliva from uninfected individuals spiked with tissue
culture-derived HIV-1 (primary isolates) and tested with RT-PCR
and the NASBA and NucliSens HIV-1 RNA assaysa
Body fluid (n samples)
No. of samples inhibited (%)
Roche Monitor NASBA
Seminal plasma (25) 24 (96) 0 (0)
CVL (5) 0 (0) 0 (0)
Breast milk (8) 3 (38) 0 (0)
CSF (5) 0 (0) 0 (0)
Saliva (6) 4 (67) 0 (0)
a Recovery of the internal standards was used to gauge either partial or
complete inhibition. Previously reported results from seminal plasma testing (4)
are provided for comparison.
TABLE 2. CVL, breast milk, and CSF from infected patients tested for HIV RNA with RT-PCR
and the NASBA and NucliSens HIV-1 RNA assaysa
Body fluid (n samples)
Result by:









Seminal plasma (25) 56 ,2.6–5.9 68 ,3–6.1
CVL (5) 100 2.4–4.3 100 2.1–4.6
Breast milk (5) 60 ,2.6–3.4 40 ,2.6–3.2
CSF (11) 73 ,2.6–4.8 27 ,2.6–4.5
a Results were compared with previous data obtained from seminal plasma (4).
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differences in sensitivity observed were not statistically signif-
icant, probably due to the small sample sizes.
Comparison of viral loads in different biological compart-
ments. To determine the detection frequency and range of
viral loads in different body fluids and to compare the associ-
ation between blood plasma and body fluid viral loads, paired
specimens from larger numbers of infected individuals were
tested (Table 3). Seminal plasma and blood plasma were tested
in the NASBA and NucliSens assays (n 5 73; Fig. 1A). Paired
CSF and blood samples were tested by RT-PCR (n 5 102; Fig.
1B). Paired CVL and blood samples (n 5 107; Fig. 1C) and
paired saliva and blood samples were tested by the NucliSens
assay (n 5 59; Fig. 1D). In all cases, HIV-1 RNA was more
frequently detected in the blood, with detection rates ranging
from 71 to 97%. Detection rates in nonblood body fluids were
typically lower, ranging from 42 to 77%. Although in most
cases viral load was higher in blood than in the corresponding
body fluid (Fig. 1B and C), there were clear cases of hyper-
production of HIV RNA in nonblood compartments relative
to blood in a few individuals, especially in seminal plasma (Fig.
1A) and saliva (Fig. 1D).
DISCUSSION
HIV is known to be transmitted via semen, breast milk,
cervical secretions (reviewed in reference 21), and, to a lesser
degree, saliva (20). From a public health perspective, it is
critical that we have the capability of accurately measuring
viral loads in different body fluids in order to ultimately pre-
vent viral transmission. Knowledge of the impact of highly
active antiretroviral therapy on viral loads in different com-
partments is critical to the understanding of the pathogenesis
of HIV infection.
Several publications provide comparative data among the
three most widely used commercial HIV RNA assays for mea-
suring blood plasma viral load: RT-PCR, NASBA or Nu-
FIG. 1. Correlation between blood plasma viral loads and viral loads from other body fluids. (A) Seminal plasma compared with blood plasma (R 5 0.33, P , 0.001).
(B) CSF compared with blood plasma (R 5 0.49, P , 0.001). (C) CVL compared with blood plasma (R 5 0.31, P , 0.001). (D) Saliva compared with blood plasma
(R 5 0.45, P , 0.0001).
TABLE 3. Paired blood plasma and either CSF, seminal plasma, CVL, or saliva samples from HIV-infected patients assayed for HIV-1 RNA
Fluid Assay (n samples)
Result for:









CSF RT-PCR (102) 71 ,2.6–6.0 42 ,2.6–6.2
Seminal plasma NASBA (73) 97 ,2.6–6.0 77 ,2.6–7.7
CVL NucliSens (107) 91 ,2.6–6.3 55 ,2.6–4.9
Saliva NucliSens (59) 76 2.6–5.9 46 ,2.6–6.6
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cliSens, and Quantiplex (5, 14, 17, 22). In contrast, methods for
evaluating HIV in nonblood compartments have yet to be
standardized, making direct comparisons between studies dif-
ficult. The most extensively studied compartment is probably
the male genital tract. Other investigators (3, 9) have now
confirmed our initial finding (4) of inhibitors in seminal plasma
which copurify with RNA in the Roche Monitor assay. These
inhibitors, however, can be effectively removed by the silica
bead isolation procedure (1) employed in NASBA-based as-
says.
Similar comparisons for other types of body fluids have
rarely been published. Early studies used noncommercial as-
says for evaluating viral load in nonblood compartments (10,
13, 15, 16, 23). Results from noncommercial assays have sel-
dom been compared with those from commercial kits and,
when tested, usually involved only blood plasma as the body
fluid evaluated (18). However, one recent study compared a
noncommercial, quantitative-competitive RT-PCR assay with
the Roche assay for the evaluation of viral load in blood and
CVL (11). In that study, the RT-PCR-based assay appeared
more sensitive than the commercial assay, although the issue of
inhibitors was not discussed.
More recently, researchers have used the Roche Monitor
assay to assess viral burden in body fluids, frequently without
apparently checking for the presence of inhibitors (2, 12, 27).
Yet other investigators have simply used the NASBA or Nu-
cliSens assay for all of their nonblood studies under the ap-
parent assumption that there might be inhibitors to the RT-
PCR method (7; A. Kovacs, P. Reichelderfer, and D. Wright,
Abstr. Int. Conf. AIDS, abstr. 23488, 1998). In addition, most
noncommercial assays use external standards for quantitation
(10, 15). The lack of internal QSs in some of these assays may
mask the presence of inhibitors. As a consequence, results
derived from these assays with some types of body fluids may
not be accurate. Our results suggest that breast milk and saliva
samples frequently contain components which inhibit the
Roche Monitor assay, although none of these specimens dem-
onstrated complete inhibition, as was observed with some sem-
inal plasma samples (4). Inhibitors were removed when the
silica bead RNA extraction method was used, mirroring our
earlier observations with seminal plasma (4). We detected no
obvious inhibition when CVLs or CSFs were assayed with the
Roche Monitor assay. Semba et al. (24), however, reported no
inhibition when the Roche Monitor assay was used with breast
milk specimens.
The Roche Monitor assay provided greater sensitivity, espe-
cially at low viral load levels. Five CSF specimens which had
undetectable viral loads with the NASBA assay had viral loads
of 620 to 950 copies/ml in the Roche assay. Although some
degree of inhibition was observed with some breast milk spec-
imens, three of five breast milk specimens from HIV-seropos-
itive women were detectable in the Roche Monitor assay com-
pared with two of five for the NASBA assay (Table 1). The
highest viral load observed in these specimens was only 2,500
copies/ml. Greater sensitivity of the NASBA or NucliSens as-
say can be achieved by increasing the sample input volume,
especially for cell-free specimens. However, care must be
taken, because uncentrifuged specimens may contain enough
cellular DNA to interfere with the Boom (1) isolation proce-
dure (J. Schock and P. Vernazza, personal observation).
In cross-sectional studies, we found that viral loads in blood
plasma were generally higher than those in corresponding body
fluids. A high blood plasma viral load typically correlated with
high viral loads in nonblood secretions. However, there were
clear exceptions. Some men have been shown to excrete very
high levels of HIV RNA in the seminal plasma (6, 28) and
should be studied further to understand their potential role as
transmitters. Similarly, a few women have extremely high cer-
vical viral loads and may be more likely to transmit the virus
either to sexual contacts or to their infants (8).
This study did not address differences in sample collection or
processing of various body fluids that may also influence viral
load. Collection of seminal plasma and CSF is straightforward,
with few, if any variations in sample collection or processing
methods among the various studies. HIV RNA in breast milk
and saliva has been assayed as unprocessed (not centrifuged)
or as cell-free supernatant. For this particular study, we used
cell-free breast milk and whole, uncentrifuged saliva. In con-
trast, methods of sample collection in the female genital tract
vary widely and have included endocervical wicks, cervical vag-
inal lavages, cervical swabs, and vaginal swabs (P. Reichelder-
fer, R. Coombs, D. Wright, D. Burns, and A. Kovacs for the
WHS 001 Study Group, Abstr. 38th Intersci. Conf. Antimicrob.
Agents Chemother., abstr. I-251, 1998). Unlike the other spec-
imens, analysis of female genital secretions usually involves a
dilution factor, due to the collection procedure, that is hard to
estimate because the exact volume of the secretion in un-
known. This study presented data on unfractionated CVL
without correcting for dilution.
We conclude that HIV-1 RNA can be accurately detected by
the NASBA- or NucliSens-based assay in all body fluids tested,
while the presence of inhibitors limits the usefulness of RT-
PCR. We also found that viral loads from nonblood sources
are typically 1 to 2 logs lower than those from matched blood
plasma samples. The existence of detectable loads in these
body fluids, however, stresses the importance of evaluating the
impact of therapeutic treatment regimens and candidate vac-
cines in both blood and nonblood fluids.
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